PAIN RELIEF INNOVATION
South Rampart Pharma is a clinical-stage life science company focused on advancing innovative small molecules designed to overcome the risks of current pain medicines.
Learn More

Our novel, non-addictive lead asset is designed to avoid the liver and kidney toxicities of currently available pain medicines.

Lead Program SRP-001 avoids liver toxicity of acetaminophen.

SRP-001 is currently in a Phase 1 clinical trial evaluating safety, tolerability, and pharmacokinetics.


WATCH OUR VIDEO

News and Milestones


  • South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant
  • LEARN MORE

  • A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.
  • LEARN MORE


  • Dr Hernan Bazan, the Co-Founder & CEO of South Rampart Pharma Featured on NPR's Tech Nation Radio
  • LEARN MORE

  • South Rampart Pharma will be presenting at the 16th annual Arrowhead Pain Therapeutics Summit in Washington, DC on November 14-15, 2022
  • VIEW AGENDA



  • South Rampart Pharma receives $1.9m NIH STTR Fast-Track Grant
  • LEARN MORE

OUR MISSION TO ADVANCE THE SAFE TREATMENT OF PAIN

Technology

Characterizing and carefully modeling the body’s metabolic pathways facilitated development of a novel molecule designed to avoid limitations of current non-opioid analgesics.

Pipeline

Our pipeline contains compounds designed to effectively treat pain and fever across a range of clinical indications, clinical settings, and dose forms.

Global Need

Patients and the healthcare systems that care for them need an alternative to addictive or potentially toxic pain medications and the heavy downstream costs they incur.